$ALMR

Qiming Corporate GP VI, Ltd. sold 280,458 indirectly-held shares of Alamar Biosciences, Inc. (ALMR) at an average of $30.56 ($29.35–$31.07, $8.57M total) across 20 trades over 2026-10-23 to 2026-10-26. Filed jointly with Qiming Managing Directors Fund VI, L.P. (10% owner), Qiming Venture Partners VI, L.P. (10% owner), Qiming GP VIII, LLC (10% owner), Qiming Venture Partners VIII Investments, LLC (10% owner), Qiming GP VIII-HC, LLC (10% owner) and Qiming Venture Partners VIII-HC, L.P. (10% owner).

Qiming Corporate GP VI, Ltd. sold 342,626 indirectly-held shares of Alamar Biosciences, Inc. (ALMR) at an average of $29.92 ($29.00–$30.81, $10.25M total) across 24 trades over 2026-10-21 to 2026-10-22. Filed jointly with Qiming Managing Directors Fund VI, L.P. (10% owner), Qiming Venture Partners VI, L.P. (10% owner), Qiming GP VIII, LLC (10% owner), Qiming Venture Partners VIII Investments, LLC (10% owner), Qiming GP VIII-HC, LLC (10% owner) and Qiming Venture Partners VIII-HC, L.P. (10% owner).

Qiming Corporate GP VI, Ltd. sold 217,512 indirectly-held shares of Alamar Biosciences, Inc. (ALMR) at an average of $27.35 ($26.34–$28.44, $5.95M total) across 16 trades over 2026-10-19 to 2026-10-20. Filed jointly with Qiming Managing Directors Fund VI, L.P. (10% owner), Qiming Venture Partners VI, L.P. (10% owner), Qiming GP VIII, LLC (10% owner), Qiming Venture Partners VIII Investments, LLC (10% owner), Qiming GP VIII-HC, LLC (10% owner) and Qiming Venture Partners VIII-HC, L.P. (10% owner).

Qiming Corporate GP VI, Ltd. sold 173,673 indirectly-held shares of Alamar Biosciences, Inc. (ALMR) at an average of $27.73 ($27.02–$28.26, $4.82M total) across 12 trades over 2026-10-15 to 2026-10-16. Filed jointly with Qiming Managing Directors Fund VI, L.P. (10% owner), Qiming Venture Partners VI, L.P. (10% owner), Qiming GP VIII, LLC (10% owner), Qiming Venture Partners VIII Investments, LLC (10% owner), Qiming GP VIII-HC, LLC (10% owner) and Qiming Venture Partners VIII-HC, L.P. (10% owner).

Alamar Biosciences' options are locked up from 16-APR-2026 to 14-OCT-2026. Directors, officers, and major shareholders agreed not to sell shares during this period. The company specializes in proteomics technology for protein detection and analysis.

Pacific Biosciences (PACB), Fortrea (FTRE), Alamar (ALMR), 10x Genomics (TXG), and Azenta (AZTA) reached 52-week highs on October 6, 2026. PACB announced a collaboration with TychoBio, FTRE reported Q2 revenue of $678M, ALMR saw Q2 revenue surge to $29.43M, TXG launched the Atera platform, and AZTA reported 12% Q3 revenue growth.

Alamar Biosciences (ALMR) appointed Bob Ragusa, former CEO of GRAIL, to its board. The company also added John Brottem as general counsel and Amelia Merrill as Chief People Officer. Ragusa's experience in genomics and diagnostics is expected to aid Alamar's mission in early disease detection using its NULISA platform.

Alamar Biosciences (ALMR) stock rose 10.3% to $38.44 in pre-market trading after reporting Q2 2026 revenue growth of 82% YoY to $29.4M and raising full-year revenue guidance to $116M-$120M. Analysts increased price targets, and the company expanded a partnership with the Alzheimer’s Disease Data Initiative.

Alamar Biosciences (ALMR) stock rose 6.8% to $34.20 in morning trading, continuing a rally since its Q2 2026 earnings report showed 82% revenue growth and a 60% gross margin. Analysts raised price targets (JPMorgan to $35, Stifel to $32, BofA to $31), maintaining Buy ratings. The company's Alzheimer’s Disease Data Initiative partnership also boosted investor interest. The broader market had minimal impact, suggesting the gains are specific to ALMR's strong fundamentals and growth prospects.

Alamar Biosciences, Inc. (ALMR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 28, 2026, the board of directors (the “Board”) of Alamar Biosciences, Inc. (the “Company”) appointed Robert Ragus